Pipeline – A

About INTASYL™

INTASYL ™ is a precision siRNA immunotherapy that targets messenger RNA, which is encoded by genes in the DNA, resulting in the reduction of specific target proteins.

INTASYL is a patented platform from which unique patented compounds are created to silence genes that tumors use to evade the immune system. These self-delivering, chemically modified siRNA compounds can be delivered to a broad range of cell types and tissues without the need for delivery enhancements. INTASYL has a simplified chemical composition that helps reduce toxicity, increase tolerability, and enhance efficacy, and it’s adaptable to both Intra-tumoral and Adoptive Cell Therapy (ACT) applications.

INTASYL compounds have demonstrated activity against multiple gene targets including PD-1, BRD4, CTLA4, TIGIT and CTGF.

How INTASYL™ Works
Clinical Development

Program

Discovery

Preclinical Proof
of Concept

IND Enabling
Studies

IND Clearance

Clinical Phase

PH-762

Read More

FULL

FULL

FULL

75%

PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells.

Target(s) & Indication: PD-1
cSCC, Advanced Melanoma, Merkel Cell

PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells.

Target(s) & Indication: PD-1
Metastatic Melanoma

PH-762

Enhanced TIL Study

(AgonOx Partner)
Read More

FULL

FULL

FULL

75%

PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells.

Target(s) & Indication: PD-1
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma, and other solid tumors

PH-894

Read More

FULL

FULL

75%

PH-894 is an INTASYL compound that silences BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.

Target(s) & Indication: BRD-4
Advanced Melanoma, Merkel Cell, HCC, TNBC

PH-804 is an INTASYL compound that targets TIGIT, a protein that inhibits the activity of Natural Killer (NK) cells.  This study demonstrated that NK cells, when treated with PH-804, increased activation and enhanced the ability of NK cells to kill cancer cells.

Target(s) & Indication: TIGIT

Key Clinical Initiatives & Programs

PH-762

  • Initiating a dose-escalation study for the treatment of advanced cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.
  • Phase 1 clinical trial, PH-762 in combination with Double Positive Tumor Infiltrating Lymphocytes (DP TILS) for the treatment of melanoma and other solid tumors (in partnership with AgonOx).
  • For more information about Phio’s clinical trials, contact clinicaltrials@phiopharma.com

PH-894

  • Pre-clinical studies have shown this compound has a dual mechanism: the suppression of BRD4 results in T cell activation and makes tumor cells more sensitive to T cell killing.
  • Pre-clinical studies of PH-894 show the compound may also have activity for the treatment of viral infections.

Scientific Resources

Investors

About us

Contact us

Follow us on LinkedIn